RESEARCH ARTICLE
Peripheral Synergistic Interaction Between Lidocaine and Lumiracoxib on the 1% Formalin Test in Rats
Mario I. Ortiz*, 1, Gilberto Castaneda-Hernandez2, Jeannett A. Izquierdo-Vega1, Hector A. Ponce-Monter1
Article Information
Identifiers and Pagination:
Year: 2011Volume: 4
First Page: 8
Last Page: 14
Publisher ID: TOPAINJ-4-8
DOI: 10.2174/1876386301104010008
Article History:
Received Date: 30/08/2011Revision Received Date: 14/10/2011
Acceptance Date: 14/10/2011
Electronic publication date: 25/11/2011
Collection year: 2010
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
It has been shown that the association of non-steroidal anti-inflammatory drugs (NSAIDs) with analgesic agents can increase their antinociceptive activity, allowing the use of lower doses and thus limiting side effects. Therefore, the aim of the present study was to examine the possible pharmacological interaction between lumiracoxib and lidocaine at the local peripheral level in the rat using the 1% formalin test and isobolographic analysis. Lumiracoxib, lidocaine or fixed-dose ratio (1:1) lumiracoxib-lidocaine combinations were administered locally in the formalin-injured paw and the antinociceptive effect was evaluated. All treatments produced a dose-dependent antinociceptive effect. ED40 values were estimated for the individual drugs and an isobologram was constructed. The derived theoretical ED40 for the lumiracoxiblidocaine combination was 599.3 ± 58.8 μg/paw, being significantly higher than the actually observed experimental ED40 value, 393.6 ± 39.7 μg/paw. This result correspond to a synergistic interaction between lumiracoxib and lidocaine at the local peripheral level, potency being about one and half times higher with regard to that expected from the addition of the effects of the individual drugs. Data suggest that low doses of the lumiracoxib-lidocaine combination can interact synergistically at the peripheral level and therefore this drug association may represent a therapeutic advantage for the clinical treatment of procedural or inflammatory pain.
